A

n experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.

In all, 82 percent of patients had their cancer shrink at least by half at some point in the study.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Good news. I am 9 months cancer free after participating in the Juno CAR 17 trial for relapsed NHL. My chemo induced peripheral neuropathy has gotten much worse. Do you have any evidence from Kite relative to patients who started their trial with my problem and how their CIPN has been affected. I can not get any response from Juno when I tell City of Hope how bad my pain and leg and hand cramping has become. Keep the info coming. I talk to lots of patients at COH who have no idea these clinical trials are out there. Steve Kohn-San Diego

    • Steve, my son participated in JUNO’s CART-15 trial. Because of the neuropathy side effect he was unable to walk. But the doctor prescribed the right physical therapy for him and it helped a lot. email me for details at mlv7@hotmail.com

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy